Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series
Tuesday, 15 January 2019 CHARLOTTESVILLE, Va., Jan. 15, 2019 (GLOBE NEWSWIRE) -- *Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)*, www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole Johnson, MD, the Company’s Chairman of the Board, was featured in a second video produced by The Doctors Channel discussing the Company’s lead asset AD04 alcohol use disorder (AUD) drug about to begin Phase 3 clinical trials. The most recent video can be viewed at:https://www.thedoctorschannel.com/view/pharmacogenetic-approach-to-treating-alcohol-use-disorder/.
The first video was made available in November 2018 and can be viewed at:
The Doctors Channel is the world’s largest video site for doctors featuring short-form accredited CME, medical news and lifestyle videos. The Doctor’s Channel reports over 450,000 physicians and clinicians in-network and has a growing video library consisting of more than 6,500 videos.
Dr. Johnson is a renowned addiction expert and currently holds a number of titles including the Dr. Irving J. Taylor Professor and Chair, Department of Psychiatry, University of Maryland. He has written and spoken extensively about Alcohol Use Disorder (AUD) and is regularly sought by authorities around the world for his expertise in the sector.“Sharing what I’ve learned and my conclusions about alcohol use disorder through The Doctors Channel with the many experts who are on the frontlines of the addiction battle is both humbling and productive as together we can share best practices and keep our collective efforts in the public eye,” said Dr. Johnson. “Our goal is to save lives and reduce the pain, suffering and loss of productivity associated with all addictions. Shared information through such respected channels will help give our efforts that much more impact.”
*About Adial Pharmaceuticals, Inc.*
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (“AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
*Forward Looking Statements*
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include commencement of the planned phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain genotypes, the potential of AD04 to treat AUD and other addictive disorders and the ability of AD04 to save lives, reduce pain, suffering and loss of productivity associated with addictions. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, the ability commence the Phase 3 clinical trials in the first half of 2019, the ability to expand the use of AD04 for use in patients with opioid use disorder, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our registration statement on Form S-1 that we have filed with the SEC and the final prospectus and our Current Report on Form 10-Q for the quarter ended September 30, 2018. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Black Dog Communications Group, Inc.
Crescendo Communications, LLC